A team of researchers at the University of Connecticut has developed a new therapeutic strategy that could stop fatty liver disease in its tracks and potentially reverse damage already caused in many patients. The breakthrough targets a long noncoding RNA called HNF4A-AS1, which controls how the liver handles fat accumulation. For a disease affecting billions of people globally, this represents a significant shift in how scientists approach treatment. Why Current Treatments Fall Short? Fatty liver disease progresses through four major stages, and the naming has recently shifted from "nonalcoholic fatty liver disease" to "metabolic dysfunction-associated steatotic liver disease" (MASLD) to reflect that it affects people of all ages, not just those who drink alcohol. The first stage, MASLD, occurs when fat begins accumulating in the liver. Most people with MASLD remain fine throughout their lives and may never need treatment. However, if the disease progresses, it can develop into metabolic dysfunction-associated steatohepatitis (MASH), which involves inflammation alongside fat accumulation. The progression is concerning: approximately 400 million people globally develop MASH, and about 50% of those patients will develop fibrosis, a scarring of the liver tissue. Of those with fibrosis, roughly 50% will progress to cirrhosis, where the liver can no longer perform its vital metabolic functions. Currently, treatment options are limited. The first line of management includes diet and exercise, but these interventions often prove insufficient because the liver can still produce fatty acids from glucose. A newer FDA-approved medication from 2024 helps some patients by activating the thyroid receptor to burn liver fat and reduce inflammation, but only a small portion of patients benefit from this option. If the disease reaches cirrhosis, the only remaining treatment is liver transplant from a matched donor. How Does the New Treatment Approach Work? The UConn research team, led by Professor Xiaobo Zhong from the School of Pharmacy and Pharmaceutical Sciences, focused on a different strategy than current drugs. Instead of targeting downstream metabolic pathways like glucose control, they identified a global regulator of liver cell function: the long noncoding RNA HNF4A-AS1. This RNA degrades HNF4A, a master regulator protein that controls the transcription of over 1,000 genes important for metabolic functioning. When HNF4A levels are low, signs of liver disease develop, including lipid accumulation, increased inflammation, insulin resistance, and impaired drug metabolism. The researchers found that in most liver disease patients, this protein is downregulated. "HNF4A seems to be an upstream master regulatory factor that controls all six pathways in fat accumulation in hepatocytes. The studies show that in most liver disease patients, this protein is down regulated," explained Xiaobo Zhong, Professor at UConn School of Pharmacy and Pharmaceutical Sciences. Xiaobo Zhong, Professor, UConn School of Pharmacy and Pharmaceutical Sciences To reverse this downregulation, the researchers developed a novel approach using antisense oligonucleotides (ASOs) and small interfering RNA (siRNA). These nucleic acid therapeutics are designed to target the HNF4A-AS1 RNA sequence so it cannot degrade HNF4A. With functional HNF4A restored, the liver is expected to function normally again. What Makes This Approach Different? Oligonucleotide-based drugs offer significant advantages over previous small molecule drug classes. They have a longer therapeutic duration, meaning patients would need fewer doses. For example, a similar siRNA drug called inclisiran for lowering cholesterol only requires administration twice per year, and this new liver treatment would likely follow a similar dosing schedule. "We think we can reverse MASH and MASLD with this approach and we think this can help open a door for pharmaceutical companies to rethink their strategy to develop a drug," stated Xiaobo Zhong. Xiaobo Zhong, Professor, UConn School of Pharmacy and Pharmaceutical Sciences The research team is now partnering with UConn's Technology Commercialization Services to translate this laboratory discovery into real-world treatment. They are actively seeking an industry partner to advance the technology, with plans to use organ-on-a-chip platforms to test candidate sequences. Once top candidates are identified, clinical studies can begin, and a drug could potentially be available on the market within several years. What Environmental Factors Are Also Putting Young People at Risk? While new treatments are being developed, emerging research reveals that young people face unexpected risk factors for fatty liver disease. A study of 284 individuals ranging from ages 8 to 23, conducted by 22 U.S. researchers and published in the journal Environmental Research, found that exposure to "forever chemicals" significantly increases fatty liver disease risk. Per- and polyfluoroalkyl substances (PFAS), commonly called "forever chemicals," are synthetic compounds that persist in the environment and accumulate in the human body over time. The study measured eight types of PFAS in participants' blood and tracked their health data over 4 to 12 years. The findings were striking: in adolescents, higher blood levels of PFOA, a common PFAS, were associated with roughly 2.7 times higher odds of developing fatty liver disease with each doubling of exposure. The risk appeared to increase with age, suggesting a cumulative effect. Older children who also carried a risk variant of a gene that regulates liver fat saw even greater risk, highlighting an interplay between genetic predisposition and environmental exposure. Among smokers, several PFAS were associated with meaningfully higher fatty liver risk. Where Are PFAS Coming From? - Food Packaging: PFAS are commonly used in food packaging materials, particularly in containers for takeout and processed foods. - Drinking Water: PFAS contamination in water supplies is a widespread concern in many communities across the United States. - Cookware and Utensils: Some types of cookware and cooking utensils made from synthetic materials can leach PFAS into food during cooking. - Processed Foods: Foods that are heavily processed or packaged tend to have higher PFAS concentrations due to their packaging materials. The study does not assert that PFAS directly cause fatty liver disease, but rather that exposure is associated with increased risk. There is likely a compounding effect: eating foods that carry the most "forever chemicals" also tends to contribute to poor metabolic health overall. What Can People Do to Reduce PFAS Exposure? - Choose Fresh Foods: Eat fresh and natural foods whenever possible rather than processed foods, which tend to have higher PFAS concentrations from packaging. - Use Natural Cookware: Replace plastic cutting boards and synthetic cooking utensils with wooden alternatives to reduce PFAS leaching during food preparation. - Avoid Black Plastic Containers: Black plastic containers, commonly used for takeout food, may heighten PFAS exposure and should be avoided when possible. - Filter Drinking Water: Consider using water filtration systems to reduce PFAS contamination in your drinking water supply. The convergence of new treatment breakthroughs and emerging environmental risk factors underscores the complexity of fatty liver disease. While the UConn research offers hope for reversing existing damage, reducing exposure to PFAS and maintaining healthy lifestyle habits remains critical for prevention, especially in young people.
